Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Inventiva (IVA – Research Report), retaining the price target of $13.00.
Ed Arce has given his Buy rating due to a combination of factors surrounding Inventiva’s recent achievements and future prospects. The company has successfully completed patient enrollment for its NATiV3 Phase 3 clinical trial, exceeding original targets and ensuring a robust sample size for statistical analysis. This trial is crucial as it evaluates the efficacy of lanifibranor, a potentially best-in-class oral therapy for MASH, with promising results anticipated given its unique mechanism of action and previous success in Phase 2b trials.
Additionally, Inventiva’s financial position is bolstered by an additional €126 million in funding, providing a cash runway through the third quarter of 2026. This financial stability is further supported by milestone payments from partnerships, such as the $10 million from Chia Tai-Tianqing Pharmaceutical Group. The company’s strategic positioning in key markets, along with the potential for significant revenue from lanifibranor, underpins the Buy rating and the price target of $13 per share.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $14.00 price target.